{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:03:02Z","timestamp":1785765782379,"version":"3.56.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","jada.ada.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of the American Dental Association"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.adaj.2025.12.014","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T04:36:40Z","timestamp":1773117400000},"page":"853-867.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of biological drugs in the treatment of xerostomia and salivary hypofunction in patients with Sj\u00f6gren disease"],"prefix":"10.1016","volume":"157","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1370-9524","authenticated-orcid":false,"given":"Juan Manuel","family":"Seoane-Romero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5575-9944","authenticated-orcid":false,"given":"Mar\u00eda Jos\u00e9","family":"Garc\u00eda-Pola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4462-5187","authenticated-orcid":false,"given":"Alba","family":"Bello-Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6175-3629","authenticated-orcid":false,"given":"Javier","family":"Seoane-Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Varela-Centelles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1354-3429","authenticated-orcid":false,"given":"Tania","family":"Gancedo-Gancedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3031-5532","authenticated-orcid":false,"given":"Pablo","family":"Castelo-Baz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.adaj.2025.12.014_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/rmdopen-2019-001064","article-title":"Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sj\u00f6gren\u2019s syndrome","volume":"5","author":"Brito-Zer\u00f3n","year":"2019","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.adaj.2025.12.014_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40744-023-00611-8","article-title":"Epidemiology of Sj\u00f6gren\u2019s: a systematic literature review","volume":"11","author":"Thurtle","year":"2024","journal-title":"Rheumatol Ther"},{"issue":"7","key":"10.1016\/j.adaj.2025.12.014_bib3","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41584-025-01268-z","article-title":"2023 International Rome Consensus for the Nomenclature of Sjogren disease","volume":"21","author":"Ramos-Casals","year":"2025","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.adaj.2025.12.014_bib4","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.39859","article-title":"Classification criteria for primary Sj\u00f6gren\u2019s syndrome: a consensus and data-driven methodology involving three international patient cohorts","volume":"69","author":"Shiboski","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.adaj.2025.12.014_bib5","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1111\/odi.12952","article-title":"Interventions for dry mouth and hyposalivation in Sj\u00f6gren\u2019s syndrome: a systematic review and meta-analysis","volume":"25","author":"Al Hamad","year":"2019","journal-title":"Oral Dis"},{"issue":"6","key":"10.1016\/j.adaj.2025.12.014_bib6","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1093\/rheumatology\/key370","article-title":"Health-related quality of life and costs in Sj\u00f6gren\u2019s syndrome","volume":"60","author":"Miyamoto","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.adaj.2025.12.014_bib7","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/eos.12358","article-title":"Oral disorders, saliva secretion, and oral health-related quality of life in patients with primary Sj\u00f6gren\u2019s syndrome","volume":"125","author":"Rusthen","year":"2017","journal-title":"Eur J Oral Sci"},{"issue":"3","key":"10.1016\/j.adaj.2025.12.014_bib8","first-page":"291","article-title":"Salivary dysfunction and quality of life in Sj\u00f6gren syndrome: a critical oral-systemic connection","volume":"139","author":"Stewart","year":"2008","journal-title":"JADA"},{"issue":"6","key":"10.1016\/j.adaj.2025.12.014_bib9","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/acr.21610","article-title":"Primary Sj\u00f6gren\u2019s syndrome as a systemic disease: a study of participants enrolled in an international Sj\u00f6gren\u2019s syndrome registry","volume":"64","author":"Malladi","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"10.1016\/j.adaj.2025.12.014_bib10","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.medcli.2022.10.007","article-title":"Sj\u00f6gren syndrome","volume":"160","author":"Brito-Zer\u00f3n","year":"2023","journal-title":"Med Clin (Barc)"},{"issue":"6","key":"10.1016\/j.adaj.2025.12.014_bib11","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1007\/s10103-014-1590-8","article-title":"Effect of laser acupuncture on salivary flow rate in patients with Sj\u00f6gren\u2019s syndrome","volume":"30","author":"Cafaro","year":"2015","journal-title":"Lasers Med Sci"},{"issue":"7","key":"10.1016\/j.adaj.2025.12.014_bib12","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/jop.13452","article-title":"Long-term effectiveness of a novel intra-oral electro-stimulator for the treatment of dry mouth in patients with Sjogren\u2019s syndrome: a randomised sham-controlled feasibility study (LEONIDAS-1)","volume":"52","author":"Fedele","year":"2023","journal-title":"J Oral Pathol Med"},{"issue":"9","key":"10.1016\/j.adaj.2025.12.014_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0162787","article-title":"High-grade salivary-gland involvement, assessed by histology or ultrasonography, is associated with a poor response to a single rituximab course in primary Sj\u00f6gren\u2019s syndrome: data from the TEARS randomized trial","volume":"11","author":"Cornec","year":"2016","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.adaj.2025.12.014_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2022.105406","article-title":"Current and future treatment in primary Sj\u00f6gren\u2019s syndrome: a still challenging development","volume":"89","author":"Ritter","year":"2022","journal-title":"Jt Bone Spine"},{"key":"10.1016\/j.adaj.2025.12.014_bib15","doi-asserted-by":"crossref","first-page":"VI53","DOI":"10.1093\/rheumatology\/keab466","article-title":"New developments in Sjogren\u2019s syndrome","volume":"60","author":"Thalayasingam","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"suppl 1","key":"10.1016\/j.adaj.2025.12.014_bib16","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/odi.13062","article-title":"World Workshop on Oral Medicine VII: Immunobiologics for salivary gland disease in Sj\u00f6gren\u2019s syndrome\u2014a systematic review","volume":"25","author":"Gueiros","year":"2019","journal-title":"Oral Dis"},{"issue":"1","key":"10.1016\/j.adaj.2025.12.014_bib17","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2014-000022","article-title":"EULAR Sj\u00f6gren\u2019s syndrome disease activity index (ESSDAI): a user guide","volume":"1","author":"Seror","year":"2015","journal-title":"RMD Open"},{"key":"10.1016\/j.adaj.2025.12.014_bib18","article-title":"Systematic review with meta-analysis: efficacy and safety of biological treatment on salivary gland function in primary Sj\u00f6gren\u2019s syndrome","volume":"14","author":"Wang","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.adaj.2025.12.014_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102590","article-title":"Early diagnosis and treatment for Sj\u00f6gren\u2019s syndrome: current challenges, redefined disease stages and future prospects","volume":"117","author":"Wang","year":"2021","journal-title":"J Autoimmun"},{"key":"10.1016\/j.adaj.2025.12.014_bib20","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.adaj.2025.12.014_bib21","first-page":"368","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline","volume":"16","author":"Campbell","year":"2020","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.adaj.2025.12.014_bib22","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/ard.61.6.554","article-title":"Classification criteria for Sjogren\u2019s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group","volume":"61","author":"Vitali","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.adaj.2025.12.014_bib23","unstructured":"RoB 2: A revised Cochrane risk-of-bias tool for randomized trials. Cochrane. Accessed January 11, 2026. https:\/\/methods.cochrane.org\/bias\/resources\/rob-2-revised-cochrane-risk-bias-tool-randomized-trials."},{"issue":"4","key":"10.1016\/j.adaj.2025.12.014_bib24","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines, 3: rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"11","key":"10.1016\/j.adaj.2025.12.014_bib25","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1136\/ard.2007.083865","article-title":"Reduction of fatigue in Sj\u00f6gren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study","volume":"67","author":"Dass","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.adaj.2025.12.014_bib26","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/art.27314","article-title":"Effectiveness of rituximab treatment in primary Sjogren\u2019s syndrome: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Meijer","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.adaj.2025.12.014_bib27","doi-asserted-by":"crossref","first-page":"233","DOI":"10.7326\/M13-1085","article-title":"Treatment of primary Sj\u00f6gren syndrome with rituximab: a randomized trial","volume":"160","author":"Devauchelle-Pensec","year":"2014","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.adaj.2025.12.014_bib28","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/art.40093","article-title":"Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sj\u00f6gren\u2019s syndrome","volume":"69","author":"Bowman","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.adaj.2025.12.014_bib29","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/art.20146","article-title":"Inefficacy of infliximab in primary Sj\u00f6gren\u2019s syndrome: results of the randomized, controlled Trial of Remicade in Primary Sj\u00f6gren\u2019s Syndrome (TRIPSS)","volume":"50","author":"Mariette","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.adaj.2025.12.014_bib30","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1136\/annrheumdis-2020-218467","article-title":"Interleukin 6 receptor inhibition in primary Sj\u00f6gren syndrome: a multicentre double-blind randomised placebo-controlled trial","volume":"80","author":"Felten","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.adaj.2025.12.014_bib31","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/art.40513","article-title":"Clinical efficacy and safety of baminercept, a lymphotoxin \u03b2 receptor fusion protein, in primary Sj\u00f6gren\u2019s syndrome: results from a phase II randomized, double-blind, placebo-controlled trial","volume":"70","author":"St Clair","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.adaj.2025.12.014_bib32","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/annrheumdis-2020-218599","article-title":"Efficacy and safety of abatacept in active primary Sj\u00f6gren\u2019s syndrome: results of a phase III, randomised, placebo-controlled trial","volume":"80","author":"Baer","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.adaj.2025.12.014_bib33","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1016\/S2665-9913(19)30160-2","article-title":"Abatacept treatment for patients with early active primary Sjogren\u2019s syndrome: a single-centre, randomised, double-blind, placebo-controlled, phase 3 trial (ASAP-III study)","volume":"2","author":"van Nimwegen","year":"2020","journal-title":"Lancet Rheumatol"},{"issue":"3","key":"10.1016\/j.adaj.2025.12.014_bib34","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/ard-2023-224691","article-title":"Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjogren\u2019s syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial","volume":"83","author":"D\u00f6rner","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"10452","key":"10.1016\/j.adaj.2025.12.014_bib35","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S0140-6736(24)01211-X","article-title":"for the TWINSS study group. Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjogren\u2019s disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study","volume":"404","author":"Fisher","year":"2024","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.adaj.2025.12.014_bib36","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/rheumatology\/keaa410","article-title":"A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjogren\u2019s syndrome","volume":"60","author":"Juarez","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.adaj.2025.12.014_bib37","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1093\/rheumatology\/kead092","article-title":"A randomized, double-blind, placebo-controlled, parallel group study on the effects of a cathepsin S inhibitor in primary Sj\u00f6gren\u2019s syndrome","volume":"62","author":"Bentley","year":"2023","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.adaj.2025.12.014_bib38","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/art.11199","article-title":"Treatment of primary Sjogren\u2019s syndrome with low-dose human interferon alfa administered by the oromucosal route: combined phase III results","volume":"49","author":"Cummins","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.adaj.2025.12.014_bib39","unstructured":"36-Item Short Form Survey (SF-36). Rand. Accessed January 13, 2026. https:\/\/www.rand.org\/health\/surveys\/mos\/36-item-short-form.html."},{"issue":"6","key":"10.1016\/j.adaj.2025.12.014_bib40","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1136\/ard.2010.143743","article-title":"EULAR Sjogren\u2019s Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren\u2019s syndrome","volume":"70","author":"Seror","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.adaj.2025.12.014_bib41","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"issue":"7","key":"10.1016\/j.adaj.2025.12.014_bib42","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1136\/annrheumdis-2021-222054","article-title":"Development and preliminary validation of the Sj\u00f6gren\u2019s Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sj\u00f6gren\u2019s syndrome","volume":"81","author":"Seror","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.adaj.2025.12.014_bib43","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.rdc.2016.03.001","article-title":"Use of biologics in Sj\u00f6gren\u2019s syndrome","volume":"42","author":"Nocturne","year":"2016","journal-title":"Rheum Dis Clin North Am"},{"issue":"2","key":"10.1016\/j.adaj.2025.12.014_bib44","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3390\/ph3020323","article-title":"Oromucosal administration of interferon to humans","volume":"3","author":"Beilharz","year":"2010","journal-title":"Pharmaceuticals (Basel)"},{"issue":"6","key":"10.1016\/j.adaj.2025.12.014_bib45","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.reuma.2018.10.014","article-title":"SER recommendations on the use of biological drugs in primary Sj\u00f6gren\u2019s syndrome","volume":"15","author":"Andr\u00e9u S\u00e1nchez","year":"2019","journal-title":"Reumatol Clin (Engl Ed)"},{"issue":"9","key":"10.1016\/j.adaj.2025.12.014_bib46","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/acr.24597","article-title":"Antibodies to both Ro52 and Ro60 for identifying Sj\u00f6gren\u2019s syndrome patients best suited for clinical trials of disease-modifying therapies","volume":"74","author":"Arma\u011fan","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"8","key":"10.1016\/j.adaj.2025.12.014_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/S2665-9913(21)00122-3","article-title":"Composite of Relevant Endpoints for Sj\u00f6gren\u2019s Syndrome (CRESS): development and validation of a novel outcome measure","volume":"3","author":"Arends","year":"2021","journal-title":"Lancet Rheumatol"},{"issue":"10","key":"10.1016\/j.adaj.2025.12.014_bib48","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1080\/1744666X.2023.2234641","article-title":"Why do drug treatments fail in Sjogren\u2019s disease? Considerations for treatment, trial design and interpretation of clinical efficacy","volume":"19","author":"Arends","year":"2023","journal-title":"Expert Rev Clin Immunol"},{"issue":"8","key":"10.1016\/j.adaj.2025.12.014_bib49","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41584-021-00634-x","article-title":"Current and future therapies for primary Sj\u00f6gren syndrome","volume":"17","author":"Seror","year":"2021","journal-title":"Nat Rev Rheumatol"},{"issue":"7-8","key":"10.1016\/j.adaj.2025.12.014_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103581","article-title":"Tailoring the treatment of inflammatory rheumatic diseases by a better stratification and characterization of the clinical patient heterogeneity: findings from a systematic literature review and experts\u2019 consensus","volume":"23","author":"Ruscitti","year":"2024","journal-title":"Autoimmun Rev"},{"issue":"11","key":"10.1016\/j.adaj.2025.12.014_bib51","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1136\/annrheumdis-2015-208304","article-title":"Towards personalised treatment in primary Sjogren\u2019s syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment","volume":"75","author":"Delli","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.adaj.2025.12.014_bib52","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/art.22536","article-title":"Improvement of Sj\u00f6gren\u2019s syndrome after two infusions of rituximab (anti-CD20)","volume":"57","author":"Devauchelle-Pensec","year":"2007","journal-title":"Arthritis Care Res"},{"issue":"3","key":"10.1016\/j.adaj.2025.12.014_bib53","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1136\/annrheumdis-2017-212268","article-title":"Effect of rituximab on a salivary gland ultrasound score in primary Sj\u00f6gren\u2019s syndrome: results of the TRACTISS randomised double-blind multicentre substudy","volume":"77","author":"Fisher","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.adaj.2025.12.014_bib54","first-page":"131","article-title":"Tumor necrosis factor-alpha and receptors for it in labial salivary glands in Sj\u00f6gren\u2019s syndrome","volume":"19","author":"Koski","year":"2001","journal-title":"Clin Exp Rheumatol"},{"issue":"11","key":"10.1016\/j.adaj.2025.12.014_bib55","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1002\/acr.22052","article-title":"Evaluation of histologic, serologic, and clinical changes in response to abatacept treatment of primary Sj\u00f6gren\u2019s syndrome: a pilot study","volume":"65","author":"Adler","year":"2013","journal-title":"Arthritis Care Res"},{"issue":"7","key":"10.1016\/j.adaj.2025.12.014_bib56","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1136\/annrheumdis-2013-204653","article-title":"Abatacept treatment reduces disease activity in early primary Sj\u00f6gren\u2019s syndrome (open-label proof of concept ASAP study)","volume":"73","author":"Meiners","year":"2014","journal-title":"Ann Rheum Dis"}],"container-title":["The Journal of the American Dental Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002817726000012?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002817726000012?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T13:41:00Z","timestamp":1785764460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002817726000012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":56,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0002817726000012"],"URL":"https:\/\/doi.org\/10.1016\/j.adaj.2025.12.014","relation":{},"ISSN":["0002-8177"],"issn-type":[{"value":"0002-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of biological drugs in the treatment of xerostomia and salivary hypofunction in patients with Sj\u00f6gren disease","name":"articletitle","label":"Article Title"},{"value":"The Journal of the American Dental Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.adaj.2025.12.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Dental Association. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}